Cayman Chemical Receives CEP for Latanoprost API from EDQM
ANN ARBOR, MI, September 14, 2021 — Cayman Chemical, leader in the synthesis, purification, and characterization of lipids, has partnered with NanoImaging Services and T&T Scientific to provide a multi-pronged platform that synthesizes, characterizes, and formulates lipid-based nanoparticles to help researchers and pharmaceutical companies alike develop vaccines and other novel therapeutics from the preclinical stage on through clinical phases and commercial manufacturing.
Cayman develops and manufactures chemical compounds for research use only (RUO) and has a separate business division that produces small molecules as Active Pharmaceutical Ingredients (API) for human and veterinary use. Read more about our product SM-102 and how the information on the SDS should be interpreted.
ANN ARBOR, MI, MAY 11, 2021—Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases.
ANN ARBOR, MI, FEBRUARY 08, 2021—Cayman Chemical’s complete assay kit, protein, antibody, and biochemical portfolio is now more accessible to Denmark, Finland, Iceland, Norway, Sweden, and the Baltic countries as well as Russia through a distribution agreement with Nordic BioSite. Headquartered in Täby, Sweden, Nordic BioSite’s sales and technical support teams operate with a ‘By Your Side’ mission to assist customers in finding the right products for their research.
ANN ARBOR, MI, NOVEMBER 05, 2020—Shovels hit the dirt yesterday as Cayman held a groundbreaking ceremony to start the buildout of a $20 million research and development facility at its headquarters on 1180 East Ellsworth Road in Ann Arbor, MI. This new 66,000 square foot, three-story structure will house Cayman’s contract services, production, and research activities and will provide common areas including a gym and a company-wide meeting space that can be adapted to accommodate a more spacious and flexible working environment. Employees should occupy the new building by the end of 2021.
ANN ARBOR, MI, OCTOBER 08, 2020—The National Institute on Aging (NIA) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.
ANN ARBOR, MI, AUGUST 10, 2020—Cayman Biomedical Research Institute (CABRI) is now accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted until September 20, 2020 for awards to be distributed by November 2, 2020. Grants range from $2,000 - $5,000 and may be awarded as individual or group grants.
ANN ARBOR, MI, AUGUST 10, 2020—Cayman and GenScript have come together to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development. “Cayman provides a complete workflow enabling the identification of peptide sequences as putative neoantigens. We are excited to add GenScript’s technical means and experience to synthesize peptides for our clients’ downstream applications and potential vaccine development,” said Dr. Michael Pisano, VP of Business Development and Contract Services at Cayman.
ANN ARBOR, MI, AUGUST 06, 2020—Cayman scientists have developed a SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit to enable semi-quantitative identification of neutralizing antibodies in human plasma or serum to the novel coronavirus that causes COVID-19. Starting approximately 4-10 days after symptom onset, SARS-CoV-2 infection can result in the production of neutralizing antibodies that bind to the viral spike protein receptor binding domain (RBD) on the S1 subunit and prevent its interaction with the human ACE2 receptor, preventing further viral entry and infection. By screening for the circulating antibodies that interrupt this binding, investigators will be able to study antibody response and recovery from infection.